<DOC>
	<DOC>NCT01328522</DOC>
	<brief_summary>Primary Objective: Assess the comparative safety and tolerability of two SAR153191 (REGN88) drug products after a single dose administration in rheumatoid arthritis patients. Secondary Objective: Assess the comparative pharmacokinetic profiles of the two SAR153191 (REGN88) drug products after a single dose administration in rheumatoid arthritis patients.</brief_summary>
	<brief_title>Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The duration of the study period per subject is 5-7 weeks broken down as follows: - Screening: 1 to 14 days, - Treatment: 1 day (2 overnight stays at the study site), - Follow-up: up to 5 weeks after dosing (an additional outpatient follow-up may be scheduled depending on the last results).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of rheumatoid arthritis (RA) &gt; or = 3 months duration. Treated for a minimum of 12 weeks with Methotrexate (MTX) prior to randomization. Treatment must be continued on a stable dose for the duration of the study. Exclusion criteria: Autoimmune disease other than RA. History of acute inflammatory joint disease other than RA. Surgery within 4 weeks prior to the screening visit or with planned elective surgery within the next 3 months. Latent or active tuberculosis. Fever (â‰¥38 C) or persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the screening visit, or history of frequent recurrent infections. Received administration of any live (attenuated) vaccine within 3 months prior to the randomization visit (eg, varicellazoster vaccine, oral polio, rabies). Received tuberculosis vaccination within 12 months prior to screening Prior therapy with a Tumor Necrosis Factor (TNF) antagonist or any other biologic agents within 3 months prior to inclusion. Known latex sensitivity. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>